[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
The main purpose of this research was to study the impact of hormonotherapy on changes of the lipid metabolism in patients with breast cancer. 451 breast cancer patients were under investigation. Depending on the treatment method, all patients were divided into four groups. The first group was composed of 117 patients who received hormonotherapy consisting of tamoxifen 20 mg/day; the second group was composed of 115 patients who received Toremifen 60 mg/day; The third group was composed of 106 patients who received Toremifen 240 mg/day; The fourth group consisted of 113 patients who received Letrozol 2,5 mg/day. To determine of lipid metabolism disorders, we estimated cholesterol fractions, triglycerides and high and low density lipoproteins both prior to the beginning of hormonotherapy, and in 3, 6, 12 months. After 12 month of hormonotherapy with Tamoxifen 20 mg/day all fractions of very low density lipoproteins were increased. Patients treated with Toremifen 240 mg/day demonstrated increase of total cholesterol and triglycerides in blood and decrease of concentration of high density lipoproteins. In the groups of patients who were treated with Toremifen 60 mg/day and Letrazol 2,5 mg/day any considerable disorders of lipid metabolism was not observed. It is concluded that hormonotherapy of the breast cancer may lead to the disorders of lipid metabolism, which may also lead to disorders of heart-vascular system.
D A
DA
Aliev
V A
VA
Azizov
T A
TA
Sadygova
R S
RS
Zeĭnalov
I N
IN
Musaev
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D008078:Cholesterol, LDL / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000453:epidemiology; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077289:Letrozole; D052439:Lipid Metabolism Disorders / Q000453:epidemiology*; D009570:Nitriles / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors; D017312:Toremifene / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D008078:Cholesterol, LDL; D004965:Estrogen Antagonists; D009570:Nitriles; D014230:Triazoles; D014280:Triglycerides; D013629:Tamoxifen; D000077289:Letrozole; D017312:Toremifene